From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

Article

Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

Recent Videos
Dr. Kelly Stratton
Image of a woman wearing a red tank top.
Image of a woman with a brown hair tied into a bun.
Related Content